State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease

References

1. 1.↵
   1. Runge VM,
   2. Ai T,
   3. Hao D, et al

   . The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiology 2011;46:807–16 doi:10.1097/RLI.0b013e318237913b pmid:22094366

   CrossRefPubMed
2. 2.↵
   1. Fraum TJ,
   2. Ludwig DR,
   3. Bashir MR, et al

   . Gadolinium-based contrast agents: a comprehensive risk assessment. J Magn Reson Imaging 2017;46:338–53 doi:10.1002/jmri.25625 pmid:28083913

   CrossRefPubMed
3. 3.↵
   1. Kallen AJ,
   2. Jhung MA,
   3. Cheng S, et al

   . Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51:966–75 doi:10.1053/j.ajkd.2007.12.036 pmid:18501784

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Sadowski EA,
   2. Bennett LK,
   3. Chan MR, et al

   . Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148–57 doi:10.1148/radiol.2431062144 pmid:17267695

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Kuo PH,
   2. Kanal E,
   3. Abu-Alfa AK, et al

   . Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007;242:647–49 doi:10.1148/radiol.2423061640 pmid:17213364

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Perazella MA,
   2. Reilly RF

   . Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease. Semin Dial 2008;21:171–73 doi:10.1111/j.1525-139X.2007.00402.x pmid:18226005

   CrossRefPubMed
7. 7.↵
   1. Morcos SK

   . Extracellular gadolinium contrast agents: differences in stability. Eur J Radiology 2008;66:175–79 doi:10.1016/j.ejrad.2008.01.025 pmid:18343072

   CrossRefPubMed
8. 8.↵
   1. Sherry AD,
   2. Caravan P,
   3. Lenkinski RE

   . Primer on gadolinium chemistry. J Magn Reson Imaging 2009;30:1240–48 doi:10.1002/jmri.21966 pmid:19938036

   CrossRefPubMed
9. 9.↵
   1. Abraham JL,
   2. Thakral C

   . Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiology 2008;66:200–07 doi:10.1016/j.ejrad.2008.01.026 pmid:18374532

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Martin DR,
    2. Krishnamoorthy SK,
    3. Kalb B, et al

    . Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010;31:440–46 doi:10.1002/jmri.22024 pmid:20099361

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Wang C,
    2. Asch D,
    3. Bashir MR

    , et al., eds. American College of Radiology Manual on Contrast Media. American College of Radiology; 2024:117
12. 12.↵
    FDA Drug Safety Communication. New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. United States Food and Drug Administration; 2010
13. 13.↵
    1. Attari H,
    2. Cao Y,
    3. Elmholdt TR, et al

    . A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis. Radiology 2019;292:376–86 doi:10.1148/radiol.2019182916 pmid:31264946

    CrossRefPubMed
14. 14.↵
    1. Nandwana SB,
    2. Moreno CC,
    3. Osipow MT, et al

    . Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology 2015;276:741–47 doi:10.1148/radiol.2015142423 pmid:25875973

    CrossRefPubMed
15. 15.↵
    1. Goldstein KM,
    2. Lunyera J,
    3. Mohottige D, et al

    . Risk of Nephrogenic Systemic Fibrosis after Exposure to Newer Gadolinium Agents. Department of Veteran’s Affairs; 2019
16. 16.↵
    1. Schieda N,
    2. van der Pol CB,
    3. Walker D, et al

    . Adverse events to the gadolinium-based contrast agent gadoxetic acid: systematic review and meta-analysis. Radiology 2020;297:565–72 doi:10.1148/radiol.2020200073 pmid:32452732

    CrossRefPubMed
17. 17.↵
    1. Zech CJ,
    2. Schwenke C,
    3. Endrikat J

    . Diagnostic efficacy and safety of gadoxetate disodium vs gadobenate dimeglumine in patients with known or suspected focal liver lesions: results of a clinical phase III study. Magn Reson Insights 2019;12:1178623X19827976 doi:10.1177/1178623X19827976 pmid:30799932

    CrossRefPubMed
18. 18.↵
    1. Lunyera J,
    2. Mohottige D,
    3. Alexopoulos AS, et al

    . Risk for nephrogenic systemic fibrosis after exposure to newer gadolinium agents: a systematic review. Ann Intern Med 2020;173:110–19 doi:10.7326/M20-0299 pmid:32568573

    CrossRefPubMed
19. 19.↵
    1. Altun E,
    2. Martin DR,
    3. Wertman R, et al

    . Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy–report from two US universities. Radiology 2009;253:689–96 doi:10.1148/radiol.2533090649 pmid:19789233

    CrossRefPubMed
20. 20.↵
    1. Bruce R,
    2. Wentland AL,
    3. Haemel AK, et al

    . Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide. Invest Radiology 2016;51:701–05 doi:10.1097/RLI.0000000000000259 pmid:26885631

    CrossRefPubMed
21. 21.↵
    1. Wang Y,
    2. Alkasab TK,
    3. Narin O, et al

    . Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011;260:105–11 doi:10.1148/radiol.11102340 pmid:21586680

    CrossRefPubMed
22. 22.↵
    1. Woolen SA,
    2. Shankar PR,
    3. Gagnier JJ, et al

    . Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med 2020;180:223–30 doi:10.1001/jamainternmed.2019.5284 pmid:31816007

    CrossRefPubMed
23. 23.↵
    1. Weinreb JC,
    2. Rodby RA,
    3. Yee J, et al

    . Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology 2021;298:28–35 doi:10.1148/radiol.2020202903 pmid:33170103

    CrossRefPubMed
24. 24.↵
    1. Farooqi S,
    2. Mumtaz A,
    3. Arif A, et al

    . The clinical manifestations and efficacy of different treatments used for nephrogenic systemic fibrosis: a systematic review. Int J Nephrol Renovasc Dis 2023;16:17–30 doi:10.2147/IJNRD.S392231 pmid:36660606

    CrossRefPubMed
25. 25.↵
    1. MacLeod CA,
    2. Gauthier I,
    3. Davenport MS, et al

    . Adverse events associated with intra-arterial administration of gadolinium-based contrast agents: a systematic review and meta-analysis. J Vasc Interv Radiology 2023;34:568–77 doi:10.1016/j.jvir.2022.11.022 pmid:36464013

    CrossRefPubMed
26. 26.↵
    1. Lange S,
    2. Mędrzycka-Dąbrowska W,
    3. Zorena K, et al

    . Nephrogenic systemic fibrosis as a complication after gadolinium-containing contrast agents: a rapid review. Int J Environ Res Public Health 2021;18:3000 doi:10.3390/ijerph18063000

    CrossRefPubMed
27. 27.↵
    1. Robic C,
    2. Port M,
    3. Rousseaux O, et al

    . Physicochemical and pharmacokinetic profiles of gadopiclenol: a new macrocyclic gadolinium chelate with high T1 relaxivity. Invest Radiology 2019;54:475–84 doi:10.1097/RLI.0000000000000563 pmid:30973459

    CrossRefPubMed
28. 28.↵
    1. Kuhl C,
    2. Csőszi T,
    3. Piskorski W, et al

    . Efficacy and safety of half-dose gadopiclenol versus full-dose gadobutrol for contrast-enhanced body MRI. Radiology 2023;308:e222612 doi:10.1148/radiol.222612 pmid:37462494

    CrossRefPubMed
29. 29.↵
    1. Loevner LA,
    2. Kolumban B,
    3. Hutoczki G, et al

    . Efficacy and safety of gadopiclenol for contrast-enhanced MRI of the central nervous system: the PICTURE randomized clinical trial. Invest Radiology 2023;58:307–13 doi:10.1097/RLI.0000000000000944 pmid:36729404

    CrossRefPubMed
30. 30.↵
    1. Nardone B,
    2. Saddleton E,
    3. Laumann AE, et al

    . Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatr Radiology 2014;44:173–80 doi:10.1007/s00247-013-2795-x pmid:24057195

    CrossRefPubMed